OPTH.US Optimi Health Corp. Common Shares
- Market cap
- USD 12.9M
- P/E
- -
- P/B
- 1.04x
- ROE
- -51.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is OPTH.US undervalued?
Graham numberThe Graham number of Optimi Health Corp. Common Shares cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Optimi Health Corp. Common Shares fundamental analysis
No fundamental analysis for Optimi Health Corp. Common Shares yet.
Optimi Health Corp. Common Shares stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Optimi Health Corp. Common Shares
Optimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada. The company manufactures controlled substances including finished MDMA and psilocybin drug products, supplying them directly to authorized clinics, pharmacies, clinical trials, and partners. The company produces and supplies MDMA, natural psilocybin, psilocin, other psychedelic substances, and functional mushrooms derived from botanical sources for health and wellness mar…
Full company profileOptimi Health Corp. Common Shares financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Optimi Health Corp. Common Shares annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | - | 80.7K | 181K | 390K | 427K | 264K |
| Gross Profit | -5.43K | -47.1K | 53.9K | -157K | 271K | -2.08M | -632K |
| Operating Income | -483K | -6.06M | -7.39M | -4.38M | -5.61M | -4.53M | -5.52M |
| EBITDA | -494K | -5.95M | -7.03M | -4.42M | -4.74M | -2.23M | -4.65M |
| Net Income | -508K | -6.02M | -7.35M | -5.19M | -6.04M | -3.72M | -6.45M |
| EPS | -1.12 | -0.12 | -2.83 | -1.79 | -2.02 | -1.16 | -1.50 |
| Balance Sheet | |||||||
| Total Assets | 6.17M | 23.5M | 16.8M | 16.5M | 14.6M | 15.2M | 18.2M |
| Total Liabilities | 883K | 2.40M | 798K | 3.28M | 4.98M | 8.65M | 5.79M |
| Shareholders' Equity | 5.29M | 21.1M | 16.0M | 13.2M | 9.58M | 6.58M | 12.4M |
| Cash & Short-term Investments | 4.47M | 12.4M | 1.89M | 1.34M | 104K | 1.15M | 9.20M |
| Total Debt | 156K | 251K | 158K | 1.71M | 2.75M | 6.69M | 3.62M |
| Cash Flow | |||||||
| Operating Cash Flow | -143K | -6.02M | -4.58M | -3.60M | -4.28M | -2.63M | -3.97M |
| Capital Expenditure | 755K | 4.94M | 7.15M | 804K | 152K | 88.4K | 40.4K |
| Free Cash Flow | -898K | -11.0M | -11.7M | -4.41M | -4.43M | -2.72M | -4.01M |
| Ratios | |||||||
| ROE | -9.6% | -28.6% | -45.9% | -39.3% | -63.0% | -56.5% | -51.9% |
| ROA | -8.2% | -25.7% | -43.7% | -31.5% | -41.5% | -24.4% | -35.4% |
| Net Profit Margin | - | - | -9,106.9% | -2,868.5% | -1,548.3% | -870.8% | -2,440.6% |
| Debt to Equity | 0.03x | 0.01x | 0.01x | 0.13x | 0.29x | 1.02x | 0.29x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Optimi Health Corp. Common Shares dividends
Optimi Health Corp. Common Shares has not paid dividends in the last 6 fiscal years.
Last stock split: 1:30 on May 20, 2026.
Who owns Optimi Health Corp. Common Shares
- Insiders 12.66%
- Institutions 10.17%
- Public & others 77.17%
- Shares outstanding 5.73M
- Free float 4.65M
Top funds holding OPTH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| AdvisorShares Psychedelics ETF | 262K | 4.57% | 0.00% | Oct 2026 |
Top institutions holding OPTH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Yorkville Advisors Global, LP | 199K | 3.48% | 0.00% | Jun 2026 |
| Mariner Wealth Advisors LLC | 122K | 2.14% | 0.00% | Jun 2026 |
| AdvisorShares Investments, LLC | 103K | 1.80% | 0.00% | Jun 2026 |
| TWO SIGMA SECURITIES, LLC | 10.6K | 0.19% | 0.00% | Jun 2026 |
| UBS Group AG | 5.87K | 0.10% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 1.96K | 0.03% | 0.00% | Jun 2026 |
| NATIONAL BANK OF CANADA /FI/ | 598.00 | 0.01% | 0.00% | Jun 2026 |
| TD Waterhouse Canada Inc | 333.00 | 0.01% | 0.00% | Jun 2026 |
| Northwestern Mutual Wealth Management Co | 136.00 | 0.00% | 0.00% | Jun 2026 |
| SRS Capital Advisors Inc | 50.00 | 0.00% | 0.00% | Jun 2026 |
Optimi Health Corp. Common Shares company profile
- Company name
- Optimi Health Corp. Common Shares
- Ticker
- OPTH.US
- ISIN
- CA68405H3080
- Exchange
- USA Stocks
- Listed since
- May 20, 2026
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 6
- Fiscal year end
- September
- Address
- 269 David Brown Way, Princeton, BC, Canada, V0X 1W0
- Phone
- 778-761-4551
- Website
- optimihealth.ca
About Optimi Health Corp. Common Shares
Optimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada. The company manufactures controlled substances including finished MDMA and psilocybin drug products, supplying them directly to authorized clinics, pharmacies, clinical trials, and partners. The company produces and supplies MDMA, natural psilocybin, psilocin, other psychedelic substances, and functional mushrooms derived from botanical sources for health and wellness markets. The company also engages in farming, processing, and distribution of raw mushroom biomass, mushroom extracts, manufacturing of drug products, and mushroom supplements. It sells its products through Amazon marketplace and distributors/brokers, as well as online. Optimi Health Corp. was incorporated in 2020 and is based in Princeton, Canada.
Optimi Health Corp. Common Shares management
8- Mr. John James WilsonCo-Founder & Chairman · born 1989
- Mr. Dane StevensCo-Founder, CEO, Corporate Secretary & Director · born 1989
- Mr. Bryan Edward SafarikCo-Founder, COO & Director · born 1985
- Mr. Jacob SafarikInterim CFO & Director · born 1988
- Dr. Preston A. ChaseChief Science Officer
- Ms. Ann LittleHuman Resources Manager
- Mr. Robert MartinChief Strategy Officer
- Dr. Michael Blough Ph.D.Chief Clinical Development Officer